East Sunshine drug impact 6 billion insulin varieties Sanofi 60% of the market is in a hurry

Recently, CDE official website shows that Yichang East Sunshine Yangtze River Pharmaceuticals insulin insulin insulin injection application was accepted.
2019, sales of end-end insulin glycelin injections in China's public medical institutions exceeded 6 billion yuan, while Sanofi's market share was the highest, according to the company's internal network data.
note that Sanofi's market share has declined in recent years, from 71% in 2014 to 61% in 2019, as domestic pharmaceutical companies have gained strength.
, insulin glycelin and its injections are a new type of insulin-like object, which has the effect of long-lasting, no peak blood concentration and smooth reduction of blood sugar in patients.
the original research manufacturer is Sanofi Avant company, the product name comes when.
was approved by the FDA and the European Pharmaceutical Products Review Board in April and June 2000 for the treatment of type 1 and type 2 diabetes, respectively;
In recent years, China's public medical institutions terminal insulin glycelin injection sales (units: 100 million yuan) Source: China's public medical institutions terminal competition pattern Mienet data show that in 2019 China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal insulin insulin injection sales exceeded 6 billion yuan, Sanofi's market share ranked first.
note that Sanofi's market share has declined in recent years, from 71% in 2014 to 61% in 2019, as domestic pharmaceutical companies have gained strength.
source: Mi Net one-click retrieval insulin glycerine injection has insulin glycerine injection and recombinant insulin glycerine injection two kinds, among them, insulin glycelin injection manufacturers have Sanofi, Zhuhai Federal Pharmaceuticals and Tonghua Dongbao Pharmaceuticals, recombinant insulin insulin injection manufacturers have glycerides pharmaceutical industry.
source: MED2.0 China Drug Review Database Up to now, insulin glycelin injections have Yichang Dong Sunshine Changjiang Pharmaceuticals and Liaoning Boao Biopharmaceuticals submitted applications for listing, recombinant insulin insulin injections have Jiangsu Wanbang Biochemical Pharmaceutical Group submitted applications for listing, are in the review and approval (in the drug review center).
data sources: CDE official website, Mienet database